EE200200547A - Neovaskularisatsiooni parendatud ravi - Google Patents

Neovaskularisatsiooni parendatud ravi

Info

Publication number
EE200200547A
EE200200547A EEP200200547A EEP200200547A EE200200547A EE 200200547 A EE200200547 A EE 200200547A EE P200200547 A EEP200200547 A EE P200200547A EE P200200547 A EEP200200547 A EE P200200547A EE 200200547 A EE200200547 A EE 200200547A
Authority
EE
Estonia
Prior art keywords
neovascularization
improved treatment
treatment
improved
Prior art date
Application number
EEP200200547A
Other languages
English (en)
Estonian (et)
Inventor
Kimbro Brazzell Romulus
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of EE200200547A publication Critical patent/EE200200547A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EEP200200547A 2000-03-24 2001-03-22 Neovaskularisatsiooni parendatud ravi EE200200547A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19180700P 2000-03-24 2000-03-24
PCT/EP2001/003265 WO2001074389A2 (en) 2000-03-24 2001-03-22 Improved treatment of neovascularization

Publications (1)

Publication Number Publication Date
EE200200547A true EE200200547A (et) 2004-02-16

Family

ID=22707008

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200547A EE200200547A (et) 2000-03-24 2001-03-22 Neovaskularisatsiooni parendatud ravi

Country Status (21)

Country Link
US (4) US20010039438A1 (de)
EP (1) EP1265636A2 (de)
JP (1) JP2003528926A (de)
KR (2) KR20020082487A (de)
CN (1) CN100398153C (de)
AR (1) AR032151A1 (de)
AU (2) AU5040101A (de)
BR (1) BR0109499A (de)
CA (1) CA2403612A1 (de)
CZ (1) CZ20023174A3 (de)
EE (1) EE200200547A (de)
HU (1) HUP0300347A3 (de)
IL (1) IL151833A0 (de)
MX (1) MXPA02009351A (de)
NO (1) NO20024486L (de)
NZ (1) NZ521360A (de)
PL (1) PL359027A1 (de)
RU (1) RU2271222C2 (de)
UA (1) UA75350C2 (de)
WO (1) WO2001074389A2 (de)
ZA (1) ZA200207638B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528926A (ja) * 2000-03-24 2003-09-30 ノバルティス アクチエンゲゼルシャフト 新血管形成の改善された処置
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
HRP20040406A2 (en) * 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
WO2004030588A2 (en) 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US20050043786A1 (en) * 2003-08-18 2005-02-24 Medtronic Ave, Inc. Methods and apparatus for treatment of aneurysmal tissue
FR2867189A1 (fr) * 2004-03-08 2005-09-09 Ludovic Bourre Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
WO2006015016A2 (en) * 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
EP2452686A3 (de) 2005-08-29 2012-09-05 HealOr Ltd. Verfahren und Zusammensetzungen zur Vorbeugung und Behandlung von diabetischer und alternder Haut
US8753673B2 (en) * 2006-05-23 2014-06-17 Taiwan Liposome Co. Ltd. Liposome composition for delivery of a therapeutic agent to eyes
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
EP2156834A1 (de) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmische pharmazeutische Zusammensetzungen enthaltend Sorafenib zur Behandlung von neoangiogenen Erkrankungen der Augen
RU2395318C1 (ru) * 2009-01-15 2010-07-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения скрытых субретинальных неоваскулярных мембран
WO2011087066A1 (ja) 2010-01-14 2011-07-21 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
RU2449821C1 (ru) * 2010-09-01 2012-05-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "МНИОИ им. П.А.Герцена Минздравсоцразвития России") Способ модификации фотодинамического лечения

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
CA2087902C (en) 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
PL172480B1 (pl) * 1992-11-20 1997-09-30 Univ British Columbia Kompozycja do niszczenia lub uszkadzania obszaru nowego unaczynienia PL PL
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
RU2144342C1 (ru) * 1996-07-18 2000-01-20 Санкт-Петербургский филиал МНТК "Микрохирургия глаза" Способ дозирования лазерной коагуляции при заболеваниях сетчатой оболочки глаза
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
EP1997513B1 (de) * 2000-02-10 2012-04-11 Massachusetts Eye & Ear Infirmary Kombinationen und Zubereitung zur Anwendung in PDT zur Behandlung von Augenleiden mit unerwünschter choriodaler Neovascularisation
JP2003528926A (ja) * 2000-03-24 2003-09-30 ノバルティス アクチエンゲゼルシャフト 新血管形成の改善された処置

Also Published As

Publication number Publication date
RU2271222C2 (ru) 2006-03-10
US20060263392A1 (en) 2006-11-23
NO20024486D0 (no) 2002-09-19
PL359027A1 (pl) 2004-08-23
WO2001074389A2 (en) 2001-10-11
WO2001074389A3 (en) 2002-07-11
NZ521360A (en) 2004-07-30
ZA200207638B (en) 2003-10-16
MXPA02009351A (es) 2003-02-12
KR20070114856A (ko) 2007-12-04
CA2403612A1 (en) 2001-10-11
US20080096865A1 (en) 2008-04-24
US8862224B2 (en) 2014-10-14
AU5040101A (en) 2001-10-15
HUP0300347A2 (hu) 2003-06-28
BR0109499A (pt) 2002-12-10
AR032151A1 (es) 2003-10-29
EP1265636A2 (de) 2002-12-18
CN100398153C (zh) 2008-07-02
KR20020082487A (ko) 2002-10-31
JP2003528926A (ja) 2003-09-30
US20120203162A1 (en) 2012-08-09
HUP0300347A3 (en) 2005-03-29
UA75350C2 (en) 2006-04-17
US20010039438A1 (en) 2001-11-08
IL151833A0 (en) 2003-04-10
AU2001250401B2 (en) 2005-08-11
NO20024486L (no) 2002-09-19
US8158669B2 (en) 2012-04-17
CZ20023174A3 (cs) 2003-01-15
CN1420788A (zh) 2003-05-28

Similar Documents

Publication Publication Date Title
DK1267650T3 (da) Tobakbehandling
NO20024486L (no) Forbedret behandling av neovaskularisering
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20032122L (no) Forbedret behandling
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DE60036093D1 (de) Antagonisten des gardos-kanals
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
NO20030978L (no) Behandling av urindysfunksjon
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
NO20024236D0 (no) Behandling av psoriasis
NO20030767L (no) Behandling av forbrenninger
NO20025765L (no) Kombinasjonssett for behandling av malaria
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit
ATE285468T1 (de) Gewebehandlungszubereitung
FI6139U1 (fi) Käyttäjäkeskeisen fysioterapian toteuttaminen
FI20002756A0 (fi) Uusi hoitomenetelmä
UA4353S (uk) Масажне кільце
FR2810531B1 (fr) Trocart de coelio-chirurgie
NO20010171D0 (no) Teknisk behandling av tåke
NO20032885D0 (no) Elektrodebehandling
SE9903421D0 (sv) Behandlingsförfarande